Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients

被引：26
|
作者：
Ashida, Atsuko [1 ]
Sakaizawa, Kaori [1 ]
Uhara, Hisashi [1 ]
Okuyama, Ryuhei [1 ]
机构：
[1] Shinshu Univ, Sch Med, Dept Dermatol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
来源：
ACTA DERMATO-VENEREOLOGICA | 2017年 / 97卷 / 10期
关键词：
melanoma; circulating tumour DNA; anti-programmed cell death-1 antibody; BRAF; NRAS; droplet digital PCR; METASTATIC MELANOMA; NRAS MUTATIONS; DIGITAL PCR; BRAF; CANCER; RESISTANCE; NIVOLUMAB; THERAPY; UTILITY; PLASMA;
D O I：
10.2340/00015555-2748
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic activity can be challenging because of tumour enlargement associated with intratumoural inflammation. Because circulating tumour DNA (ctDNA) correlates with tumour burden, we assessed the value of ctDNA levels as an indicator of tumour changes. Quantification of ctDNA (BRAF(mutant) or NRAS(mutant)) levels by droplet digital PCR in 5 patients with BRAF or NRAS mutant melanoma during the treatment course showed dynamic changes corresponding to radiological and clinical alterations. In 3 cases in which the anti-PD-1 antibody was effective, ctDNA levels decreased within 2-4 weeks after treatment initiation. In 2 cases in which the anti-PD-1 antibody was ineffective, ctDNA levels did not decrease after treatment initiation. ctDNA could be a useful biomarker to predict early response to treatment in patients with advanced melanoma treated with anti-PD-1 immunotherapy.
引用
收藏
页码：1212 / 1218
页数：7
相关论文
共 50 条
  • [1] Circulating tumor DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients
    Ashida, A.
    Sakaizawa, K.
    Uhara, H.
    Okuyama, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S291 - S291
  • [2] Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
    Gopalakrishnan, V.
    Spencer, C. N.
    Nezi, L.
    Reuben, A.
    Andrews, M. C.
    Karpinets, T. V.
    Prieto, P. A.
    Vicente, D.
    Hoffman, K.
    Wei, S. C.
    Cogdill, A. P.
    Zhao, L.
    Hudgens, C. W.
    Hutchinson, D. S.
    Manzo, T.
    de Macedo, M. Petaccia
    Cotechini, T.
    Kumar, T.
    Chen, W. S.
    Reddy, S. M.
    Sloane, R. Szczepaniak
    Galloway-Pena, J.
    Jiang, H.
    Chen, P. L.
    Shpall, E. J.
    Rezvani, K.
    Alousi, A. M.
    Chemaly, R. F.
    Shelburne, S.
    Vence, L. M.
    Okhuysen, P. C.
    Jensen, V. B.
    Swennes, A. G.
    McAllister, F.
    Sanchez, E. Marcelo Riquelme
    Zhang, Y.
    Le Chatelier, E.
    Zitvogel, L.
    Pons, N.
    Austin-Breneman, J. L.
    Haydu, L. E.
    Burton, E. M.
    Gardner, J. M.
    Sirmans, E.
    Hu, J.
    Lazar, A. J.
    Tsujikawa, T.
    Diab, A.
    Tawbi, H.
    Glitza, I. C.
    SCIENCE, 2018, 359 (6371) : 97 - 103
  • [3] Predicting tumour response to anti-PD-1 immunotherapy with computational modelling
    Valentinuzzi, Damijan
    Simoncic, Urban
    Ursic, Katja
    Vrankar, Martina
    Turk, Marusa
    Jeraj, Robert
    PHYSICS IN MEDICINE AND BIOLOGY, 2019, 64 (02):
  • [4] Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Maecker, Holden
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [5] Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
    Lee, J. H.
    Long, G. V.
    Boyd, S.
    Lo, S.
    Menzies, A. M.
    Tembe, V.
    Guminski, A.
    Jakrot, V.
    Scolyer, R. A.
    Mann, G. J.
    Kefford, R. F.
    Carlino, M. S.
    Rizos, H.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1130 - 1136
  • [6] Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure
    Klee, Gina
    Kurzhals, Jonas
    Hagelstein, Victoria
    Zillikens, Detlef
    Recke, Andreas
    Langan, Ewan A.
    Terheyden, Patrick
    MELANOMA RESEARCH, 2021, 31 (05) : 464 - 471
  • [7] Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma
    Yaru Gao
    Yue Huo
    Lingli Wang
    Jiayi Ruan
    Lanzhen Chen
    Hongdong Li
    Guini Hong
    Scientific Reports, 15 (1)
  • [8] Circulating tumor DNA (ctDNA) in the detection of relapse in melanoma patients with adjuvant anti-PD-1 therapy
    Forschner, Andrea
    Niessner, Heike
    Sinnberg, Tobias
    Eigentler, Thomas
    Amaral, Teresa
    Seith, Ferdinand
    Garbe, Claus
    Biskup, Saskia
    Battke, Florian
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 (06): : 867 - 871
  • [9] Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy
    Keller, Laura
    Guibert, Nicolas
    Casanova, Anne
    Brayer, Stephanie
    Farella, Magali
    Delaunay, Myriam
    Gilhodes, Julia
    Martin, Elodie
    Balague, Gisele
    Favre, Gilles
    Pradines, Anne
    Meyer, Nicolas
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (02) : 206 - 210
  • [10] Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients
    Martinovic, Katarina Mirjacic
    Vuletic, Ana
    Miletic, Nevena Tisma
    Zizak, Irina Besu
    Milovanovic, Jelena
    Matkovic, Suzana
    Jurisic, Vladimir
    TRANSLATIONAL ONCOLOGY, 2023, 38
12345